The DOI matches its Crossref record.
Amorphous Drug Nanosuspensions. 1. Inhibition of Ostwald Ripening
Abstract
Amorphous drug nanosuspensions are prone to particle growth due to Ostwald ripening. By incorporating a second component of extremely low aqueous solubility, Ostwald ripening can be inhibited. These studies indicate that to inhibit ripening, the drug/inhibitor mixture (in the particles) must form a single phase. The drug/inhibitor mixture can be characterized by the interaction parameter chi using the Bragg-Williams theory, in which single phase mixtures are obtained for chi < 2. The chi parameter can be calculated from the (crystalline) solubility of the drug in the inhibitor, provided the inhibitor is a liquid, and the melting entropy and temperature of the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
When poor solubility becomes an issue: From early stage to proof of concept
Stegemann, S., Leveiller, F., Franchi, D., de Jong, H., & Lindén, H. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.05.110 · Cited by 567
Thorat, A. A., & Dalvi, S. V. (2012) · Chemical Engineering Journal · doi:10.1016/j.cej.2011.12.044 · Cited by 438
Nanoparticle formulations in pulmonary drug delivery
Bailey, M. M., & Berkland, C. J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20140 · Cited by 302
Ghosh, I., Bose, S., Vippagunta, R., & Harmon, F. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.051 · Cited by 265
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Metadata
- Authors
- Lindfors, L., Skantze, P., Skantze, U., Rasmusson, M., Zackrisson, A., & Olsson, U.
- Venue
- Langmuir
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-12-21
- Volume
- 22
- Issue
- 3
- Pages
- 906-910
- ISSN
- 0743-7463 (ISSN-L)
- 1520-5827
- OpenAlex
- W2028883574
- Cited by
- 197
- References
- 0
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.